Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.

被引：0

作者：

Zhao, Kuaile

Kim, Sung-Bae

Kato, Ken

Hsu, Chih-Hung

Hu, Sheng

Wang, Feng

Kojima, Takashi

Kim, Young Saing

Van Cutsem, Eric

Ajani, Jaffer A.

Li, Liyun

Ding, Ningning

Tao, Aiyang

Shen, Lin

机构：

[1] Fudan Canc Hosp, Dept Radiat Oncol, Shanghai, Peoples R China

[2] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea

[3] Natl Canc Ctr, Dept Head & Neck Esophageal Med Oncol, Tokyo, Japan

[4] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

[5] Hubei Canc Hosp, Wuhan, Peoples R China

[6] Zhengzhou Univ, Henan Canc Hosp, Dept Med Oncol, Affiliated Canc Hosp 1, Zhengzhou, Peoples R China

[7] Natl Canc Ctr Hosp East, Dept Gastrointestinal Oncol, Kashiwa, Japan

[8] Gachon Univ, Dept Internal Med, Gil Med Ctr, Incheon, South Korea

[9] Univ Hosp Gasthuisberg Leuven, Dept Digest Oncol, Leuven, Belgium

[10] Katholieke Univ Leuven, Leuven, Belgium

[11] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX USA

[12] BeiGene Ltd, Zhongguancun Life Sci Pk, Beijing, Peoples R China

[13] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Dept Gastrointestinal Oncol, Minist Educ Beijing, Beijing, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e16107

引用

页码：E16107 / E16107

页数：1

共 50 条

[1] Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup
Zhao, Kuaile
Kim, Sung-Bae
Kato, Ken
Hsu, Chih-Hung
Hu, Sheng
Wang, Feng
Kojima, Takashi
Kim, Young Saing
Van Cutsem, Eric
Ajani, Jaffer A.
Li, Liyun
Ding, Ningning
Tao, Aiyang
Shen, Lin
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[2] Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302) in the overall population and Europe/North America subgroup
Ajani, J.
El Hajbi, F.
Cunningham, D.
Alsina, M.
Thuss-Patience, P.
Scagliotti, G.
Van den Eynde, M.
Rybkin, I.
Shen, L.
Kato, K.
Kim, S.
D'Alonzo, S.
Yu, W.
Tao, A.
Van Cutsem, E.
ANNALS OF ONCOLOGY, 2021, 32 : S225 - S225
[3] RATIONALE 302: Randomized, Phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma
Van Cutsem, Eric
Kato, Ken
Kim, Sung-Bae
Ajani, Jaffer
Zhao, Kuaile
He, Zhiyong
Yu, Xinmin
Shu, Yonqian
Luo, Qi
Wang, Jufeng
Chen, Zhendong
Niu, Zuoxing
Sun, Jong-Mu
Lin, Chen-Yuan
Hara, Hiroki
Pazo-Cid, Roberto
Borg, Christophe
Li, Liyun
Tao, Aiyang
Shen, Lin
JOURNAL OF TRANSLATIONAL MEDICINE, 2022, 20 (SUPPL 1)
[4] RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma.
Shen, Lin
Kato, Ken
Kim, Sung-Bae
Ajani, Jaffer A.
Zhao, Kuaile
He, Zhiyong
Yu, Xinmin
Shu, Yongqian
Luo, Qi
Wang, Jufeng
Chen, Zhendong
Niu, Zuoxing
Sun, Jong Mu
Lin, Chen-Yuan
Hara, Hiroki
Pazo-Cid, Roberto
Borg, Christophe
Li, Liyun
Tao, Aiyang
Van Cutsem, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[5] Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
Shen, Lin
Kato, Ken
Kim, Sung-Bae
Ajani, Jaffer A.
Zhao, Kuaile
He, Zhiyong
Yu, Xinmin
Shu, Yongqian
Luo, Qi
Wang, Jufeng
Chen, Zhendong
Niu, Zuoxing
Zhang, Longzhen
Yi, Tienan
Sun, Jong-Mu
Chen, Jianhua
Yu, Guohua
Lin, Chen-Yuan
Hara, Hiroki
Bi, Qing
Satoh, Taroh
Pazo-Cid, Roberto
Arkenau, Hendrick-Tobias
Borg, Christophe
Lordick, Florian
Li, Liyun
Ding, Ningning
Tao, Aiyang
Shi, Jingwen
Van Cutsem, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (26) : 3065 - +
[6] Second-line tislelizumab vs chemotherapy in advanced or metastatic ESCC: RATIONALE 302 Japanese subgroup
Hara, Hiroki
Satoh, Taroh
Kojima, Takashi
Motoyama, Satoru
Tsushima, Takahiro
Sunakawa, Yu
Okada, Morihito
Tao, Aiyang
Ding, Ningning
Kato, Ken
ANNALS OF ONCOLOGY, 2022, 33 : S468 - S468
[7] Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302
Hiroki Hara
Taroh Satoh
Takashi Kojima
Takahiro Tsushima
Yu Sunakawa
Morihito Okada
Ningning Ding
Hongqian Wu
Liyun Li
Tian Yu
Gisoo Barnes
Ken Kato
Esophagus, 2024, 21 : 102 - 110
[8] Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302
Hara, Hiroki
Satoh, Taroh
Kojima, Takashi
Tsushima, Takahiro
Sunakawa, Yu
Okada, Morihito
Ding, Ningning
Wu, Hongqian
Li, Liyun
Yu, Tian
Barnes, Gisoo
Kato, Ken
ESOPHAGUS, 2024, 21 (02) : 102 - 110
[9] Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study
Ajani, J.
El Hajbi, F.
Cunningham, D.
Alsina, M.
Thuss-Patience, P.
Scagliotti, G. V.
Van den Eynde, M.
Kim, S-b.
Kato, K.
Shen, L.
Li, L.
Ding, N.
Shi, J.
Barnes, G.
Van Cutsem, E.
ESMO OPEN, 2024, 9 (01)
[10] Rational 302: randomized Phase III Trial of Tislelizumab vs. Chemotherapy as Second-line Therapy for advanced unresectable/metastatic Esophageal Squamous Cell Carcinoma
Moehler, M.
Shen, L.
Kato, K.
Kim, S. B.
Ajani, J.
Zhao, K.
He, Z.
Yu, X.
Shu, Y.
Luo, Q.
Wang, J.
Chen, Z.
Niu, Z.
Sun, J. M.
Lin, C. Y.
Hara, H.
Pazo-Cid, R.
Borg, C.
Li, L.
Tao, A.
Cutsem, E. V.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 166 - 166

← 1 2 3 4 5 →